Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) EBT Margin (2016 - 2025)

Karyopharm Therapeutics' EBT Margin history spans 14 years, with the latest figure at 264.44% for Q4 2025.

  • For Q4 2025, EBT Margin rose 36584.0% year-over-year to 264.44%; the TTM value through Dec 2025 reached 2.47%, up 5016.0%, while the annual FY2025 figure was 2.47%, 5016.0% up from the prior year.
  • EBT Margin reached 264.44% in Q4 2025 per KPTI's latest filing, up from 75.14% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 300.22% in Q4 2023 to a low of 246.2% in Q1 2021.
  • Average EBT Margin over 5 years is 59.4%, with a median of 91.92% recorded in 2023.
  • Peak YoY movement for EBT Margin: surged 41467bps in 2023, then crashed -40162bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 54.37% in 2021, then plummeted by -311bps to 114.45% in 2022, then surged by 362bps to 300.22% in 2023, then tumbled by -134bps to 101.4% in 2024, then surged by 361bps to 264.44% in 2025.
  • Per Business Quant, the three most recent readings for KPTI's EBT Margin are 264.44% (Q4 2025), 75.14% (Q3 2025), and 98.11% (Q2 2025).